Melanoma Clinical Trials (2026): 434 Recruiting Interventional Studies

Last updated: April 17, 2026

Current Clinical Trial Landscape

Active research areas in 2026:

Neoadjuvant immunotherapy combinations (nivo+ipi before surgery) — multiple Phase 3 trials
TIL (tumor-infiltrating lymphocyte) cell therapy for checkpoint-refractory disease
LAG-3 + PD-1 combinations (relatlimab + nivolumab and next-gen agents)
Bispecific antibodies: tebentafusp (HLA-A*02:01, uveal melanoma), brenetafusp (IMC-F106C)
Oncolytic virus therapy (OH2, T-VEC combinations)

Standard of care: Checkpoint immunotherapy (nivolumab ± ipilimumab) for most patients. BRAF/MEK inhibitors (dabrafenib + trametinib, encorafenib + binimetinib) for BRAF V600-mutant melanoma. Immunotherapy first, targeted therapy second — even for BRAF-mutant patients.

Recruiting Trials by Treatment Setting

Neoadjuvant / Perioperative (Stage III Resectable)

Immunotherapy before and/or after surgery — a rapidly evolving area with practice-changing results:

Immunotherapy combinations:
- NCT06794775 - SWE-NEO: Monotherapy vs combined immunotherapy in resectable melanoma (Phase 3)
- NCT05770102 - DETERMINE: Atezolizumab in adult and pediatric melanoma (Phase 3)

Advanced / Metastatic — First-Line

Checkpoint immunotherapy is standard first-line. Trials test new combinations and novel agents:

Next-gen checkpoint combinations:
- NCT06246916 - Anti-LAG-3 + anti-PD-1 combinations in advanced melanoma (Phase 3)
- NCT06697301 - EIK1001 + pembrolizumab vs placebo + pembrolizumab first-line (Phase 3)
- NCT07459543 - Nivolumab + relatlimab (LAG-3) fixed-dose combination (Phase 4)
Bispecific antibodies:
- NCT05549297 - Tebentafusp vs investigator's choice in advanced melanoma (Phase 3)

Advanced / Metastatic — After Prior Immunotherapy

Options after checkpoint failure — TIL therapy, oncolytic virus, TCR-T, and novel mechanisms:

TIL cell therapy:
- NCT05727904 - Lifileucel (TIL) + pembrolizumab vs pembrolizumab alone (Phase 3)
TCR-T cell therapy:
- NCT06743126 - SUPRAME: IMA203 (PRAME TCR-T) vs investigator's choice (Phase 3)
Oncolytic virus:
- NCT05868707 - OH2 oncolytic virus injection in melanoma (Phase 3)
Novel combinations:
- NCT06624644 - LNS8801 ± pembrolizumab in refractory melanoma (Phase 3)
- NCT03646617 - Ipilimumab + nivolumab ± hypofractionated radiotherapy (Phase 2)

Uveal / Ocular Melanoma

A distinct subtype with different biology — tebentafusp and darovasertib are leading approaches:

- NCT06246149 - Adjuvant tebentafusp in high-risk ocular melanoma (Phase 3)
- NCT07015190 - Neoadjuvant darovasertib in primary uveal melanoma (Phase 3)
- NCT06519266 - PHP + ipi/nivo vs ipi/nivo alone in uveal melanoma with liver mets (Phase 3)

Showing selected notable trials. View all 434 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find melanoma clinical trials I'm eligible for?

Enter your melanoma details into ClinTrialFinder — including BRAF/NRAS mutation status, stage, and prior treatments. The AI matches you with trials based on your specific profile in minutes.

What melanoma trials are currently recruiting?

There are 434 recruiting interventional trials for melanoma including checkpoint immunotherapy combinations, BRAF/MEK targeted therapy, TIL cell therapy, oncolytic virus therapy, and bispecific antibodies.

Find Melanoma Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.

Find Matching Trials